<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988559</url>
  </required_header>
  <id_info>
    <org_study_id>J0866, NA_00020850</org_study_id>
    <secondary_id>P50CA098252</secondary_id>
    <secondary_id>1R21CA128232</secondary_id>
    <nct_id>NCT00988559</nct_id>
  </id_info>
  <brief_title>Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)</brief_title>
  <official_title>A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the efficacy and safety of different routes of administration of a DNA
      vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment
      groups. Subjects enrolled in the first two groups will receive vaccination intradermally with
      a needle-free delivery device. Subjects enrolled in groups 3 and 4 will receive vaccination
      intramuscularly. Subjects enrolled in groups 5 and 6 will receive vaccine intralesionally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

        -  To evaluate the feasibility and toxicity of vaccination in women with CIN2/3 caused by
           HPV16

        -  To evaluate the effect of vaccination on histology

        -  To compare immunogenicity of three different routes of administration: intradermal (ID),
           intramuscular (IM), intralesional (IL).

      Secondary Objectives:

        -  To evaluate changes in HPV viral load

        -  To evaluate the cellular immune response to vaccination

        -  To evaluate the humoral immune response to vaccination

        -  To evaluate local tissue immune response

        -  To correlate measures of immune response with clinical response

        -  To correlate measures of immune response with those observed in the preclinical model
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate feasibility and toxicity in women with CIN2/3 caused by HPV16</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare immunogenicity of three different routes of administration: intradermal (ID), intramuscular (IM), and intralesional (IL)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>HPV16+</condition>
  <condition>Cervical Intraepithelial Neoplasia (CIN 2/3)</condition>
  <arm_group>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA vaccination</intervention_name>
    <description>vaccination with pNGVL4a-CRT/E7(detox)</description>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <other_name>Therapeutic vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gene gun vaccine</intervention_name>
    <description>8 micrograms (group 1) or 16 micrograms (group 2)</description>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <other_name>PMED administration</other_name>
    <other_name>ND10 device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intramuscular vaccination</intervention_name>
    <description>1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly</description>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <other_name>DNA vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intra-lesional vaccine administration</intervention_name>
    <description>1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally</description>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <other_name>Intra-lesional DNA vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic resection of the lesion</intervention_name>
    <description>at week 15, all residual lesions will be resected</description>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <other_name>LEEP or cold knife conization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod</intervention_name>
    <description>imiquimod applied to the cervix by the physician</description>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with high grade cervical intraepithelial lesions (CIN2/3)

          -  patients whose lesions are HPV16+

          -  patients who are age 18 or older

          -  patients who are able to give informed consent

          -  patients who are immunocompetent

          -  patients who are not pregnant, committed to using adequate contraception if of
             childbearing age

          -  patients who have a minimum hemoglobin level of 9

        Exclusion Criteria:

          -  Patients with cytologic evidence of glandular dysplasia

          -  Patients with cytologic evidence of adenocarcinoma in situ

          -  Patients who are pregnant

          -  Patients with an active autoimmune disease

          -  Patients who are taking immunosuppressive medication

          -  Patients with concurrent malignancy except for nonmelanoma skin lesions

          -  Patients who have an allergy to gold.

          -  Patients with any evidence of damaged skin, or moles, scars, tattoos or marks at the
             proposed site(s) of administration that might interfere with the interpretation of
             local skin reactions.

          -  History or evidence of a physician-diagnosed chronic or recurrent inflammatory skin
             disease (e.g. psoriasis, eczema, atopic dermatitis, hypersensitivity) at the proposed
             site of administration in the past 5 years.

          -  Patients who have an active autoimmune disease or history of autoimmune disease
             requiring medical treatment with systemic immunosuppressants, including: inflammatory
             bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis,
             hemolytic anemic, or immune thrombocytopenia, rheumatoid arthritis, SLE, and Sjogren's
             syndrome, sarcoidosis. Asthma or COPD that does not require systemic corticosteroids
             or routine use of inhaled steroids is acceptable

          -  Patients who have received prior chrysotherapy (administration of gold salts to treat
             rheumatoid arthritis).

          -  Patients with a history of arterial or venous thrombosis

          -  Patients with non-healed wounds.

          -  Patients with a history of keloid formation ( ID delivery group only)

          -  Patients with a history of hepatitis B with persistent infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Trimble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Office Sidney Kimmel Comprehensive Cancer Center</last_name>
    <phone>410-955-8804</phone>
    <email>jhcccro@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warner K Huh, MD</last_name>
      <phone>205-996-4662</phone>
      <email>warner.huh@ccc.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ronald Alvarez, MD</last_name>
      <phone>205-996-4662</phone>
      <email>ronald.alvarez@ccc.uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Warner K Huh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Alvarez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Outpatient Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinsmedicine.org/cervicaldysplasia</url>
    <description>Johns Hopkins Center for Cervical Dysplasia</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high grade cervical dysplasia</keyword>
  <keyword>treatment vaccine</keyword>
  <keyword>therapeutic</keyword>
  <keyword>HPV</keyword>
  <keyword>DNA vaccine</keyword>
  <keyword>gene therapy</keyword>
  <keyword>gene gun</keyword>
  <keyword>pre-cancerous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 27, 2016</submitted>
    <returned>December 20, 2016</returned>
    <submitted>March 29, 2018</submitted>
    <returned>May 1, 2018</returned>
    <submitted>May 11, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

